The Promise of Percutaneous Transhepatic Variceal Embolization for Both Gastroesophageal and Ectopic Varices—An Australian Case Series

Chaitanya Ambati1, Mark Danta2, David Boshell1, Jesse Ende1, David Williams2, Joga Chaganti1, -

1Department of Medical Imaging, St Vincent’s Hospital, Sydney, Australia
2Department of Gastroenterology, St Vincent’s Hospital, Sydney, Australia

Abstract
Purpose This article aims to report Australian experience of percutaneous transhepatic embolization of gastroesophageal and ectopic varices.

Method Eight consecutive patients (mean age 61.8 years, 7 men) who had undergone percutaneous transhepatic variceal embolization (PTVE) for variceal bleeding between October 2013 and February 2020 were analyzed. All patients were admitted from the emergency department. The following embolic materials were used—coils, Onyx 18 (Medtronic), and n-butyl cyanoacrylate plus lipiodol.

Results Post-PTVE, all eight patients demonstrated clinical and radiological improvement in the immediate postprocedure period (< 24 hours). Patients were followed for a mean of 44 ± 24 days postprocedure. Two patients were lost to follow-up. The postprocedure complications included rebleeding (n = 1), hepatic encephalopathy (n = 1), hemoperitoneum (n = 1), ileus (n = 1), and abdominal pain (n = 3).

Conclusion PTVE is an effective treatment option for patients with uncontrolled variceal bleeding (ectopic as well as gastroesophageal) especially when the traditional therapies such as transjugular intrahepatic portosystemic shunts, endoscopic variceal ligation, and balloon-occluded retrograde transvenous obliteration are contraindicated or ineffective.

Introduction
Variceal bleeding is a serious complication of portal hypertension and a leading cause of death in patients with liver cirrhosis. Gastroesophageal varices are present in approximately 50% of patients with cirrhosis and their presence correlates with severity of liver disease.1 Endoscopic variceal ligation (EVL) is considered the endoscopic treatment of choice for esophageal variceal bleeding; however, treatment failure with this regime occurs in approximately 10 to 15% of patients.7 Furthermore, EVL cannot be performed on patients with ectopic varices, such as ileal or anorectal. In such cases and in those with advanced cirrhosis where recurrent variceal bleeding is a problem,3,5 transjugular intrahepatic portosystemic shunt (TIPS) has emerged as a superior alternative to EVL over the past two decades.6,7 However, TIPS is not without its own complications such as stent occlusion and an increased risk of hepatic encephalopathy (HE).8,9 Balloon-occluded retrograde transvenous obliteration (BRTO) is another option and is a popular treatment for gastric varices in Japan.10 However, it cannot be performed...
in patients without catheterizable gastrorenal shunts. In such patients, percutaneous transhepatic variceal embolization (PTVE) can still be used and has shown satisfactory results.11,12

PTVE is an alternative technique to manage both gastroesophageal and ectopic variceal bleeding that was first described in 1974.13 Although reports confirmed its efficacy in controlling bleeding in approximately 70 to 90% of patients, it has not gained widespread adoption as the procedure was initially complicated by variceal recurrence and rebleeding in approximately 37 to 65% of patients within a few months after PTVE.14,18,19 However, the development of newer embolic materials has led to numerous reports on the successful use of PTVE in the management of uncontrolled variceal bleeding secondary to cirrhotic portal hypertension. We report our experience of PTVE in patients with both gastroesophageal and ectopic variceal bleeding.

**Method**

A search of the St Vincent’s Public Hospital (Sydney, NSW, Australia) record databases identified eight patients who underwent PTVE between October 2013 and February 2020 and were included in this study. One patient who underwent an attempted PTVE was also identified but was excluded from this study as no embolization was performed. This case series meets the requirements of the National Statement on Ethical Conduct in Human Research as approved by St Vincent’s Hospital Human Research Ethics Committee (reference LNR/17/SVH/173).

Patient symptoms ranged from typically large volume hematemesis to melena, hypotension, and tachycardia. All patients had cirrhosis and portal hypertension. Only one patient (case 3) had features of HE. All patients received octreotide and pantoprazole infusions, packed red blood cell transfusions, and intravenous fluids before undergoing any endoscopic or radiological interventions.

Inclusion criteria for PTVE were as follows: (1) cirrhosis confirmed on imaging and laboratory examinations, (2) variceal bleeding not controlled by EVL or rebleeding occurred after EVL, and (3) patent portal vein identified on preoperative imaging. Exclusion criteria were: (1) coronary artery disease, cardiopulmonary insufficiency, or severe hypertension; (2) portal vein thrombosis; and (3) concomitant hepatocellular carcinoma or other malignancy.

Five patients (cases 1, 2, 3, 7, and 8) underwent EVL or attempted EVL as a first line procedure. All patients had abdominal sonograms prior to the procedure and four patients (5, 6, 7, and 8) also had recent multiphase computed tomography (CT) imaging (within 6 weeks of the procedure). Patients were promptly transferred to the angiographic suite if uncontrolled bleeding was recognized, which we defined as hematemesis, melena, or bleeding from ectopic sites (e.g., umbilical varices) with no other potential source of bleeding identified (such as an ulcer). After discharge, patients were given instructions for outpatient clinic follow-up with their treating gastroenterologist in 4 to 6 weeks. Cases 2 and 8 also had endoscopy at follow-up.

**Results**

**Demographics and Follow-Up**

The mean age was 61.8 ± 16.3 years and only one patient was female. Preprocedure Model for End-Stage Liver Disease (MELD) scores were retrospectively calculated and had a mean of 17 ± 5. Response to PTVE was confirmed initially angiographically and later clinically in the immediate (< 24 hours) postoperative period. All eight cases showed a good angiographic result with initial clinical hemostasis in 100% of cases (< Tables 1 and 2). One patient (case 3) had an episode of rebleeding (melena) 6 days after PTVE (while still an inpatient), for which adjunctive EVL was performed to good effect. However, after discharge from hospital, none had rebleeding when assessed at their routine short-term outpatient clinic follow-up at a mean of 44 ± 24 days postprocedure (range 18–77). Although there was no evidence of rebleeding, adjunctive EVL was also attempted.
Table 1  Details of patients

<table>
<thead>
<tr>
<th>Case</th>
<th>Age</th>
<th>Sex</th>
<th>Primary diagnosis</th>
<th>MELD score</th>
<th>Symptoms</th>
<th>Site</th>
<th>Other treatments</th>
<th>Date of PTVE</th>
<th>Follow-up (d)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>43</td>
<td>M</td>
<td>Alcoholic cirrhosis</td>
<td>15</td>
<td>Large volume hematemesis</td>
<td>Esophageal</td>
<td>Attempted EVL</td>
<td>October 2, 2013</td>
<td>69</td>
</tr>
<tr>
<td>2</td>
<td>50</td>
<td>M</td>
<td>Cirrhosis secondary to hepatitis B</td>
<td>19</td>
<td>2 d of hematemesis and melena</td>
<td>Esophageal</td>
<td>EVL 2 y prior as primary prophylaxis and attempted EVL at presentation</td>
<td>February 24, 2014</td>
<td>21</td>
</tr>
<tr>
<td>3</td>
<td>50</td>
<td>M</td>
<td>Alcoholic cirrhosis</td>
<td>12</td>
<td>Hematemesis and hepatic encephalopathy</td>
<td>Esophageal</td>
<td>EVL 3 wk prior followed by failed TIPS</td>
<td>July 30, 2014</td>
<td>77</td>
</tr>
<tr>
<td>4</td>
<td>93</td>
<td>F</td>
<td>Primary biliary cirrhosis</td>
<td>16</td>
<td>Per-rectal bleed</td>
<td>Rectal</td>
<td>Previously failed surgical management of hemorrhoids</td>
<td>August 12, 2015</td>
<td>37</td>
</tr>
<tr>
<td>5</td>
<td>64</td>
<td>M</td>
<td>Alcoholic cirrhosis</td>
<td>12</td>
<td>Per-rectal bleed</td>
<td>Ileal</td>
<td>Nil</td>
<td>June 25, 2014</td>
<td>–</td>
</tr>
<tr>
<td>6</td>
<td>60</td>
<td>M</td>
<td>Cirrhosis secondary to alcohol and hepatitis C</td>
<td>14</td>
<td>Bleeding from umbilical varices</td>
<td>Umbilical</td>
<td>Nil</td>
<td>May 16, 2018</td>
<td>–</td>
</tr>
<tr>
<td>7</td>
<td>78</td>
<td>M</td>
<td>Nonalcoholic steatohepatitis cirrhosis</td>
<td>21</td>
<td>Hematemesis</td>
<td>Gastric fundal and esophageal</td>
<td>Attempted EVL</td>
<td>November 2, 2018</td>
<td>39</td>
</tr>
<tr>
<td>8</td>
<td>48</td>
<td>M</td>
<td>Alcoholic cirrhosis</td>
<td>27</td>
<td>Hematemesis and melena</td>
<td>Esophageal</td>
<td>Failed EVL 2 wk prior (bands dislodged)</td>
<td>November 22, 2018</td>
<td>18</td>
</tr>
</tbody>
</table>

Abbreviations: EVL, endoscopic variceal ligation; MELD, Model for End-Stage Liver Disease; PTVE, percutaneous transhepatic variceal embolization; TIPS, transjugular intrahepatic portosystemic shunts.

Table 2  Treatment details and complications

<table>
<thead>
<tr>
<th>Case</th>
<th>Treatment</th>
<th>Treatment details</th>
<th>Procedure-related complications</th>
<th>Complications due to underlying liver pathology</th>
<th>Management of complications</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Onyx 18</td>
<td>10.5 mL (7 vials)</td>
<td>Clinically insignificant portal vein thrombus and ileus</td>
<td>Nil</td>
<td>Conservative</td>
</tr>
<tr>
<td>2</td>
<td>NBCA</td>
<td>6 mL diluted to 60% with lipiodol</td>
<td>Nil</td>
<td>Abdominal pain (from ascites) and right pleural effusion (nonbilious)</td>
<td>Paracentesis and thoracentesis</td>
</tr>
<tr>
<td>3</td>
<td>Onyx 18</td>
<td>9 mL (6 vials)</td>
<td>Small volume hemoperitoneum</td>
<td>Rebleeding presenting as melena (6 d post-PTVE)</td>
<td>EVL for rebleeding; Conservative management for minor hemoperitoneum</td>
</tr>
<tr>
<td>4</td>
<td>Nester coils and NBCA</td>
<td>5 mL NBCA diluted to 50% and coils 8 cm × 3–11 mm</td>
<td>Nil</td>
<td>Abdominal pain (from ascites)</td>
<td>Paracentesis</td>
</tr>
<tr>
<td>5</td>
<td>Onyx 18</td>
<td>4.5 mL (3 vials)</td>
<td>Nil</td>
<td>Nil reported (lost to follow-up)</td>
<td>–</td>
</tr>
<tr>
<td>6</td>
<td>NBCA</td>
<td>6 mL diluted to 60% with lipiodol</td>
<td>Nil</td>
<td>Nil reported (lost to follow-up)</td>
<td>–</td>
</tr>
<tr>
<td>7</td>
<td>NBCA</td>
<td>8 mL diluted to 40% with lipiodol</td>
<td>Clinically insignificant nontarget pulmonary embolization</td>
<td>Hepatic encephalopathy</td>
<td>3 d of 2-hourly 30-mL lactulose</td>
</tr>
<tr>
<td>8</td>
<td>Nester coils and NBCA</td>
<td>5 mL diluted to 50% with lipiodol and coils 7 cm × 3 mm</td>
<td>Nil</td>
<td>Abdominal pain (from ascites)</td>
<td>Paracentesis</td>
</tr>
</tbody>
</table>

Abbreviations: EVL, endoscopic variceal ligation; NBCA, n-butyl cyanoacrylate; PTVE, percutaneous transhepatic variceal embolization.
in case 2 (3 weeks post-PTVE) as prophylaxis and due to an initial failed EVL attempt. However, banding was postponed due to large volume food residue. Cases 5 and 6 were lost to follow-up.

During long-term follow-up, none of our patients represented to the emergency department or outpatient clinic with rebleeding at 1 year postprocedure. At 2 years, however, there was one fatality (case 7) at 475 days postprocedure and one patient (case 3) presented with rebleeding at 412 days postprocedure, which was treated with EVL. At 3 years, there were no new deaths or cases of rebleeding. Excluding cases immediately lost to follow-up, cumulative survival and rebleeding-free rates were calculated using the Kaplan–Meier method and charted (Figs. 1 and 2). Over 3 years, mean survival was 2.66 years (95% confidence interval [CI]: 2.07–3.23) and mean time before rebleeding was 2.69 years (95% CI: 2.13–3.25).

Cases of Gastroesophageal Varices

Five of our cases (1, 2, 3, 7, and 8) presented with gastroesophageal variceal bleeding. All five cases showed complete variceal obliteration as determined by postembolization portal venography and there were no immediate postprocedural complications (Tables 1 and 2). Only case 2 presented with large volume ascites that required drainage (using 10-F and 12-F multipurpose catheters) prior to PTVE. A total of 4 L was drained throughout the procedure. Case 3 was technically difficult and required multiple punctures to successfully access the portal vein. For case 8, we demonstrated successful variceal obliteration after deflating a Sengstaken-Blakemore tube (inserted preprocedure) on postprocedure portal venography (Fig. 3).

Cases of Ectopic Varices

Three of our cases (4, 5, and 6) presented with ectopic variceal bleeding (Tables 1 and 2). All three cases showed complete variceal obliteration as determined by postembolization venography. Case 4 demonstrated a normal variant on portomesenteric venography where the inferior mesenteric vein drained into the superior mesenteric vein. Furthermore, we used both coils and NBCA to embolize varices encircling the lower anus (Fig. 4). Case 5 presented with pelvic ileal varices (Fig. 5A) from the superior mesenteric vein draining into the right internal iliac vein. 5-F sheaths were also inserted into the left femoral artery and vein to exclude a preprocedure clinical suspicion of an arteriovenous malformation. Case 6 presented with bleeding from an umbilical hernia site from varices arising from a recanalized umbilical vein, which was successfully embolized along with incidental gastroesophageal varices from the coronary vein.

Complications

We experienced no significant complications during the procedure itself; however, several cases had postprocedure complications (Table 2). Case 1 had a small thrombus at the origin of the main portal vein, which was identified on
a multiphase CT performed 6 days after the procedure for abdominal distension and dilated bowel loops seen on a plain radiograph (diagnosed as ileus). In addition to the rebleeding experienced 6 days post-PTVE in case 3, there was also minor perihepatic contrast extravasation and small volume hemoperitoneum seen on a multiphase CT performed 7 hours postprocedure with a decrease in hemoglobin by 5 g/L. This complication likely occurred as a result of the multiple unsuccessful punctures made due to technical difficulty. Case 6 had a small amount of nontarget embolization to the lungs, which was diagnosed fluoroscopically at the time of the procedure. None of our cases experienced bowel ischemia or bile leaks. Cases 2, 4, and 8 all experienced abdominal distension and pain from ultrasound-proven ascites that required inpatient paracentesis for symptomatic relief. Case 2 also developed a large right pleural effusion (nonbilious), which was percutaneously drained without complication. Case 7 developed grade 4 (West Haven criteria) HE lasting 3 days, managed with 2 hourly 30-mL lactulose.

Discussion

Although introduced over four decades ago, recent advances in radiological techniques and modern embolic agents have led us to explore the use of PTVE as a treatment for uncontrolled variceal hemorrhage. Following an episode of acute variceal bleeding, patients with cirrhosis are at a high risk of recurrent bleeding and increased mortality. However, PTVE has been shown to be an effective and safe method for preventing these complications.\(^\text{21}\) Our suggested approach to a patient presenting with variceal bleeding is shown in Fig. 6.

Esophageal Varices

Esophageal varices result from portal hypertension leading to the formation of portosystemic collateral vessels. These typically occur at the junction of the coronary vein and short gastric veins (portal circulation) and the distal esophageal veins related to the azygos vein (systemic circulation). Esophageal veins are located within the lower esophageal wall, while paraesophageal and periesophageal veins are situated outside of the lower esophageal wall.\(^\text{22}\) The coronary (left gastric) vein, which divides into anterior and posterior branches, supplies these vessels. Specifically, the anterior branch supplies the esophageal veins and the posterior branch forms the para- and periesophageal veins. The incidence of severe para- and periesophageal collateral veins is high in recurrent varices, and as a result, the embolization of these feeding vessels is as important as the esophageal veins.\(^\text{22}\)

Gastric Varices

Gastric varices are less prevalent and less likely to bleed than esophageal varices; however, when bleeding does occur, they are associated with higher mortality\(^\text{23–25}\) and where endoscopic treatment has shown limited long-term success.\(^\text{26}\) As described earlier, BRTO is a widely used, successful, and accepted treatment of gastric varices in Japan.\(^\text{10}\) A variation of BRTO in the form of vascular plug-assisted retrograde transvenous obliteration (PARTO) is gaining popularity as it is technically easier to perform, avoids many shortcomings of BRTO, and has shown greater success rates for treating refractory HE and gastric variceal bleeding.\(^\text{27,28}\) However, neither BRTO or PARTO can be performed if patients do not have a catheterizable gastrorenal shunt.\(^\text{29,30}\) Furthermore, there are only a few scattered case reports on the use of BRTO for ectopic varices,\(^\text{31–36}\) none of which include rectal varices. For these patients, PTVE can still be performed.\(^\text{11,12}\) We successfully used PTVE to treat case 7, where a large gastric varix (Fig. 7) seen on CT was also identified by endoscopy but deemed unsuitable for treatment.

Fig. 4 Portal venography depicting: (A) Rectal varices from the inferior mesenteric vein; (B) Postembolization state with coils and n-butyl cyanoacrylate.

Fig. 5 (A) Computed tomography (CT) showing ileal varices. (B) Ileal varices from the superior mesenteric vein. (C) Systemic collateralization to internal iliac vein. (D) Postembolization state with Onyx 18.
Ectopic Varices

While most literature concentrates on gastroesophageal variceal bleeding, we show that ectopic variceal bleeding can be just as important. In cases 4, 5, and 6, we show that patients with ileal varices (from the superior mesenteric vein), rectal varices (from the inferior mesenteric vein), and umbilical varices (from a recanalized umbilical vein) respectively could be treated in an emergency setting with complete angiographic obliteration of varices and clinical hemostasis.

Endoscopic Variceal Ligation

Current endoscopic therapies such as variceal ligation only obliterate mucosal and submucosal varices, without any effect on feeding vessels. PTVE is advantageous in allowing for the embolization of a wider venous network, including feeding vessels. Zhang et al. compared rates of variceal recurrence and rebleeding among groups of patients based on areas of venous embolization, and found these complications were lower in patients who had embolization of a more diverse venous network, specifically left gastric vein, vessels around the gastric fundus, and variceal lower esophageal veins. However, if the embolic material fails to reach the lower esophageal veins and instead gathers in the gastric cardia vessels, EVL would be required as adjunctive treatment.

Adjunctive EVL was in fact required for case 3 for rebleeding and also attempted for case 2 for prophylaxis. This combination therapy has also been shown to be effective in reducing variceal recurrence and rebleeding rates. Over 1 to 3 years’ follow-up, our one case of rebleeding compares favorably with Wang et al., who found that only 4 out of 32 patients (12.5%) developed rebleeding for PTVE (over a similar follow-up period), compared with 17 out of 45 for EVL. However, we also showed that in case 8, PTVE can be successful in controlling esophageal bleeding when bands from prior EVL become dislodged.

Transjugular Intrahepatic Portosystemic Shunt

Aside from PTVE, studies have shown that TIPS is also more effective than endoscopic therapy at treating uncontrolled variceal bleeding. Tian et al., however, completed a retrospective study comparing TIPS and PTVE, and they found that both procedures were comparable in preventing variceal rebleeding. However, PTVE offered statistically significant better survival rates of 96.7, 72.0, and 36% at 1, 3, and 5 years in patients with MELD scores greater than 18. These numbers are comparable to our case series, which only had three cases of MELD scores > 18, with 100% survival at 1 year, and 67% at 2 years.

In our case series, PTVE was elected over TIPS by the treating clinicians for patients presenting with gastroesophageal variceal bleeding to reduce the risk of HE. Tian et al. also showed a statistically significant lower incidence of HE in PTVE patients (16.67%) compared with TIPS patients (58.14%). This compares favorably to our case series where only one of our patients developed HE.

Modern Embolic Materials (Cyanoacrylate and Onyx)

The use of cyanoacrylate as an embolic material has been found to be effective in numerous recent studies. Extensive 2-octyl cyanoacrylate variceal obliteration of lower esophageal and paraesophageal varices, submucosal varices, and the adventitial plexus of the cardia and fundus has been demonstrated on CT and portal venography. Importantly, PTVE with cyanoacrylate simultaneously obliterates the feeding vessel (for example, the gastric vein), which means that concurrent gastric and cardiac varices are eradicated along with esophageal varices. This is unlike EVL, which can induce and aggravate concurrent gastric varices. This is partly due to the material being permanently retained in paraesophageal veins without a time-dependent decrease. Cyanoacrylate was used successfully in cases 2, 4, 6, 7, and 8. In all cases, we diluted the embolic agent with...
lipiodol (see – Table 2) to delay polymerization time to reach a maximum number of varices. This is particularly useful in patients with slow flow in varices and in those without large draining vessels.\(^7\)

In cases 1, 3, and 5, we used the proprietary liquid embolic agent Onyx 18. This agent has been successfully used in neurovascular procedures, such as cerebral aneurysms and arteriovenous malformations.\(^8\) Recent research has also suggested its use in the gastrointestinal tract with a high success rate in vascular embolization.\(^4\) Our case series is the first to document the use of Onyx 18 as an embolic agent in a PTVE procedure for both gastroesophageal and ectopic varices.

**Limitations**

There are several limitations in our study. The most glaring is the relatively small number of cases, which limits the use of any meaningful quantitative statistical analyses. Furthermore, no defined protocol with a set timeframe for medium- to long-term follow-up was implemented. This is compounded by the inherent limitations of retrospective data collection, where two cases were lost to follow-up. Ideally, a large-scale, prospective study or randomized controlled trial with strict equal time to follow-up over a longer term should be performed.

**Conclusion**

Early results from our case series are consistent with the literature, showing that PTVE (using NBCA/Onyx 18 alone or in combination with coils) for management of uncontrolled variceal bleeding is a safe and effective treatment option. In line with recent studies, our case series also highlights favorable rates of recurrent variceal bleeding and HE of PTVE compared with both EVL and TIPS. We show that PTVE is particularly promising for treating ectopic varices (in addition to gastroesophageal) and when other methods such as TIPS, EVL, and BRTO are contra-indicated or ineffective.

**Conflict of Interest**

None declared.

**References**

The Promise of Percutaneous Transhepatic Variceal Embolization for Both Gastroesophageal and Ectopic Varices

Ambati et al.

39  Loffroy RF, Abualsaud BA, Lin MD, Rao PP. Recent advances in endovascular techniques for management of acute nonvariceal upper gastrointestinal bleeding. World J Gastrointest Surg 2011;3(7):89–100